CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

"This launch represents a major expansion of our professional learning portfolio, enabling us to provide even more impactful ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

KCNK13 was identified by Cerevance's proprietary NETSseq platform. About Solengepras (formerly CVN424) Solengepras is ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in Parkinson’s disease.

Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Jonah Comstock delves into what makes this team ...

On 2 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease, Cerevance announced that solengepras failed to meet its primary endpoint—change from baseline ...

US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to placebo in a Phase II study. The biotech ...

Image credit: Shutterstock / R Photography Background. US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Solengepras, the most advanced investigational treatment in Cerevance’s pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson’s disease. A brain-penetrant, specific ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated ...